HABA LaboratoriesInc Bilan de santé

Santé financière contrôle des critères 4/6

HABA LaboratoriesInc possède un total de capitaux propres de ¥8.3B et une dette totale de ¥2.1B, ce qui porte son ratio d'endettement à 25.5%. Son actif total et son passif total sont ¥12.1B et de ¥3.7B. L'EBIT de HABA LaboratoriesInc est ¥66.0M ce qui fait que son ratio de couverture des intérêts 6. Elle dispose de liquidités et de placements à court terme de ¥3.7B.

Informations clés

25.5%

Ratio d'endettement

JP¥2.13b

Dette

Ratio de couverture des intérêts	6x
Argent liquide	JP¥3.73b
Fonds propres	JP¥8.33b
Total du passif	JP¥3.72b
Total des actifs	JP¥12.06b

Mises à jour récentes de la santé financière

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Feb 19

Recent updates

What Type Of Returns Would HABA LaboratoriesInc's(TYO:4925) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 09

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Feb 19

Should You Be Impressed By HABA LaboratoriesInc's (TYO:4925) Returns on Capital?

Feb 01

Is HABA Laboratories,Inc. (TYO:4925) A Smart Choice For Dividend Investors?

Jan 13

HABA Laboratories,Inc.'s (TYO:4925) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Dec 25

What Kind Of Investors Own Most Of HABA Laboratories,Inc. (TYO:4925)?

Dec 07

A Look At HABA LaboratoriesInc's (TYO:4925) Share Price Returns

Nov 19

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4925 ( ¥8.7B ) dépassent ses passifs à court terme ( ¥2.7B ).

Passif à long terme: Les actifs à court terme de 4925 ( ¥8.7B ) dépassent ses passifs à long terme ( ¥989.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 4925 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 4925 est passé de 15.6% à 25.5% au cours des 5 dernières années.

Couverture de la dette: Le flux de trésorerie opérationnel de 4925 est négatif, par conséquent la dette n'est pas bien couverte.

Couverture des intérêts: Les paiements d'intérêts de 4925 sur sa dette sont bien couverts par l'EBIT ( 6 x couverture).

HABA LaboratoriesInc Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Haba Laboratories Ordinary Shares to Be Deleted from Other OTC

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Recent updates

HABA Laboratories,Inc. to Report Q2, 2025 Results on Nov 13, 2024

New major risk - Financial data availability

Full year 2024 earnings released: JP¥560 loss per share (vs JP¥187 loss in FY 2023)

HABA Laboratories,Inc. to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings released: JP¥560 loss per share (vs JP¥187 loss in FY 2023)

HABA Laboratories,Inc., Annual General Meeting, Jun 23, 2024

HABA Laboratories,Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Upcoming dividend of JP¥40.00 per share

Third quarter 2024 earnings released: JP¥150 loss per share (vs JP¥153 loss in 3Q 2023)

HABA Laboratories,Inc. to Report Q3, 2024 Results on Feb 09, 2024

Second quarter 2024 earnings released: JP¥34.38 loss per share (vs JP¥23.80 loss in 2Q 2023)

HABA Laboratories,Inc. to Report Q2, 2024 Results on Nov 10, 2023

First quarter 2024 earnings released: JP¥56.86 loss per share (vs JP¥37.02 loss in 1Q 2023)

HABA Laboratories,Inc. to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: JP¥187 loss per share (vs JP¥71.14 loss in FY 2022)

Full year 2023 earnings released: JP¥187 loss per share (vs JP¥71.14 loss in FY 2022)

HABA Laboratories,Inc., Annual General Meeting, Jun 18, 2023

Upcoming dividend of JP¥40.00 per share at 1.7% yield

Third quarter 2023 earnings released: JP¥153 loss per share (vs JP¥17.19 loss in 3Q 2022)

HABA Laboratories,Inc. to Report Q3, 2023 Results on Feb 10, 2023

Second quarter 2023 earnings released: JP¥23.80 loss per share (vs JP¥49.98 loss in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: JP¥23.80 loss per share (vs JP¥49.98 loss in 2Q 2022)

HABA Laboratories,Inc. to Report Q2, 2023 Results on Nov 11, 2022

First quarter 2023 earnings released: JP¥37.02 loss per share (vs JP¥72.72 loss in 1Q 2022)

Haba Laboratories Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released: JP¥71.14 loss per share (vs JP¥57.12 profit in FY 2021)

HABA Laboratories,Inc. to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: JP¥71.14 loss per share (vs JP¥57.12 profit in FY 2021)

HABA Laboratories,Inc., Annual General Meeting, Jun 19, 2022

Less than half of directors are independent

HABA Laboratories,Inc. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥40.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: JP¥49.98 loss per share (vs JP¥1.59 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥72.72 loss per share (vs JP¥51.57 loss in 1Q 2021)

Full year 2021 earnings released: EPS JP¥57.12 (vs JP¥339 in FY 2020)

Full year 2021 earnings released: EPS JP¥57.12 (vs JP¥339 in FY 2020)

Upcoming dividend of JP¥40.00 per share

What Type Of Returns Would HABA LaboratoriesInc's(TYO:4925) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

New 90-day high: JP¥4,515

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS JP¥30.15 (vs JP¥42.27 in 3Q 2020)

New 90-day high: JP¥4,350

Should You Be Impressed By HABA LaboratoriesInc's (TYO:4925) Returns on Capital?

Is HABA Laboratories,Inc. (TYO:4925) A Smart Choice For Dividend Investors?

HABA Laboratories,Inc. to Report Q3, 2021 Results on Feb 12, 2021

HABA Laboratories,Inc.'s (TYO:4925) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

What Kind Of Investors Own Most Of HABA Laboratories,Inc. (TYO:4925)?

A Look At HABA LaboratoriesInc's (TYO:4925) Share Price Returns

Second quarter 2021 earnings released: JP¥1.59 loss per share

New 90-day low: JP¥4,055

HABA Laboratories,Inc. to Report Q2, 2021 Results on Nov 11, 2020

First quarter earnings released

New 90-day low - JP¥4,060

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines